## NOTICE TO THE BAR

## MULTICOUNTY LITIGATION (MCL) – PROPOSED CONCLUSION OF MCL DESIGNATION OF THE BENICAR (OLMESARTAN MEDOXOMIL) <u>LITIGATION</u>

By Order of July 14, 2015, the Supreme Court designated all New Jersey state court litigation alleging personal injuries resulting from treatment with Benicar (Olmesartan Medoxomil) medications as multicounty litigation (MCL) and assigned it to Atlantic County for centralized management. By Order of April 15, 2019, the MCL was reassigned to Superior Court Judge John C. Porto. Judge Porto has reported to the Administrative Director of the Courts that all active litigation has resolved and that the MCL designation of the Benicar litigation therefore should be concluded.

In accordance with the provisions of Court Rule 4:38A and Directive #02-19, "Multicounty Litigation Guidelines and Criteria for Designation (Revised)," this Notice therefore is to advise of the proposed conclusion of the MCL designation of the New Jersey state-court Benicar litigation.

Anyone wishing to comment on or object to this application should provide such comments or objections in writing, with relevant supporting documentation, by **August 26, 2022** to:

Glenn A. Grant Administrative Director of the Courts Attention: Proposed Conclusion of Benicar MCL Hughes Justice Complex, P.O. Box 037 Trenton, New Jersey 08625-0037

Comments/objections may also be sent by email to <a href="mailto:Comments.mailbox@njcourts.gov">Comments.mailbox@njcourts.gov</a>.

A copy of Judge Porto's report and recommendation is posted with this Notice on the Judiciary website at <a href="www.njcourts.gov">www.njcourts.gov</a> in the Multicounty Litigation Information Center (http://www.njcourts.gov/attorneys/mcl/index.html).

Glenn A. Grant

Administrative Director of the Courts

Dated: July 8, 2022